Valiant Tan, M.D.
744 N Battlefield Blvd, Suite 200
Chesapeake, VA 23320
Valiant Tan, M.D.
University of Santo Tomas, Phillipines
Interfaith Medical Center, Brooklyn, NY
New York Medical College - Metropolitan Hospital, Chief Resident
Hematology-Oncology - Albert Einstein College of Medicine, New York
- Medical Oncology
Dr. Tan is board certified in Medical Oncology and Hematology. He has advanced the practice of cancer medicine at Virginia Oncology Associates (VOA) since 1998 and presently serves as Laboratory Director at VOA’s Elizabeth City location.
Prior to relocating to Virginia and joining VOA, Dr. Tan served residents of Bayonne, New Jersey in both private practice and as Attending Physician and Transfusion Committee Chairman at Bayonne Hospital. During his hospital tenure, he was a member of the Bloodless Surgery Program and Comprehensive Cancer Care committees, as well as Co-Investigator of the hospital’s Autologous Stem Cell Program.
Dr. Tan received his Bachelor of Science in Biology, Biology Accelerated Program, Cum Laude, and his Doctor of Medicine degrees from University of Santo Tomas, Manila, Philippines. Post graduation he completed a Rotating Internship at Chinese General Hospital, Manila, Philippines, and a Clinical Research Fellowship at Central Clinic and Hospital Taipei, Taiwan.
Dr. Tan completed his Internal Medicine Residency at both the New York Medical College Metropolitan Hospital New York, New York, where he served as Chief Resident, and as well his Internship at Interfaith Medical Center, Brooklyn, New York. His Hematology/Oncology Fellowship was completed Albert Einstein College of Medicine Montefiore Medical Center, Bronx, New York.
Dr. Tan remains a proponent of academics and research. Earlier in his career he completed in-depth studies of Non-Small Cell Lung Cancer and Patients with Unresectable Malignancy at Albert Einstein Cancer Center. His work was presented at the American Society of Clinical Oncology’s annual meetings. He continues to participate and enroll patients in clinical trials.